Xencor Inc cotiza a 25.04 USD y tiene una capitalización bursátil de $1.9B. En los últimos 12 meses ha facturado $105M con un margen de flujo de caja libre del -110.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis opti…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.29 | $-1.71 | $-0.09 |
| Estimado | $-0.40 | $-0.82 | $-0.75 | $-0.58 |
| Sorpresa | — | +64.6% | -128.0% | +84.5% |
| Métrica | XNCR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -141.3% | -38.6% | -102.7% |
| Net Margin | -73.2% | -33.6% | -39.6% |
| FCF Margin | -110.1% | -13.9% | -96.3% |
| ROE | -14.5% | -40.4% | +25.9% |
| ROA | -10.5% | -32.0% | +21.5% |
| Current Ratio | 6.25 | 2.84 | +3.41 |
| Debt / Equity | 0.12 | 0.28 | -0.16 |